Replagal Dosage/Direction for Use

Replagal treatment should be supervised by a physician experienced in the management of patients with Fabry Disease or other inherited metabolic diseases.
Posology: Replagal is administered at a dose of 0.2 mg/kg body weight every other week by intravenous infusion over 40 minutes.
Special populations: Elderly patients: Studies in patients over the age of 65 years have not been performed and no dosage regimen can presently be recommended in these patients as safety and efficacy have not yet been established.
Patients with hepatic impairment: No studies have been performed in patients with hepatic impairment.
Patients with renal impairment: No dose adjustment is necessary in patients with renal impairment.
The presence of extensive renal damage (eGFR <60mL/min) may limit the renal response to enzyme replacement therapy. Limited data are available in patients on dialysis or post-kidney transplantation, no dose adjustment is recommended.
Paediatric population: The safety and efficacy of Replagal in children aged 0-6 years has not yet been established. Currently available data are described in Pharmacology: Pharmacodynamics under Actions but no recommendation on posology can be made.
In clinical studies of children (7-18 years) who received Replagal 0.2 mg/kg every other week, no unexpected safety issues were encountered (see Pharmacology: Pharmacodynamics under Actions).
Method of administration: For instructions on dilution of the medicinal product before administration, see Special precautions for disposal and other handling under Cautions for Usage.
Administer the infusion solution over a period of 40 minutes using an intravenous line with an integral filter.
Do not infuse Replagal concomitantly in the same intravenous line with other agents.
Replagal home infusion, and administration by the patient in presence of a responsible adult or administration by the patient's caregiver (self-administration), may be considered for patients who are tolerating their infusions well. The decision to have a patient move to home infusion and/or self-administration should be made after evaluation and recommendation by the treating physician.
Appropriate training should be given by the treating physician and/or nurse to the patient and/or caregiver prior to initiation of self-administration. Dose and infusion rate should remain constant while at home, and not be changed without supervision of a healthcare professional. Self-administration should be closely followed by the treating physician.
Any patients experiencing adverse events during the home infusion/self-administration need to immediately stop the infusion process and seek the attention of a healthcare professional. Subsequent infusions may need to occur in a clinical setting.